Research peptides held in Australian stock, every lot tested by HPLC and mass spectrometry. For laboratory research use only.
Cart 0

Retatrutide vs Tirzepatide: How They Compare, With Semaglutide Too

The whole retatrutide vs tirzepatide question turns on a single receptor. Both molecules hit GIP and GLP-1, but retatrutide also engages the glucagon receptor, and in its own trials it delivered bigger average weight reductions than tirzepatide did in its trials. The two sit in very different places legally. Retatrutide is still an investigational drug, whereas tirzepatide already reaches Australian pharmacies under the Mounjaro name, and no trial pitting one directly against the other has published results.

Three Incretin Compounds Side by Side

TirzepatideRetatrutideSemaglutide
Class of agonistDualTripleSingle
Receptor targetsGIP and GLP-1GIP, GLP-1 and glucagonGLP-1
Maker and development codeEli Lilly, LY3298176Eli Lilly, LY3437943Novo Nordisk
Approximate half-life5 days6 days7 days
Chain length39 residues39 residues31 residues
Headline obesity trialSURMOUNT-1 (NEJM 2022)Phase 2 (NEJM 2023), TRIUMPH-1STEP 1 (NEJM 2021)
Mean weight loss, highest dose20.9% at 72 weeks (15 mg)28.3% at 80 weeks (TRIUMPH-1 topline), 24.2% at 48 weeks (phase 2)14.9% over 68 weeks on 2.4 mg
Formats at AminoLab3 mL pen10 mg pen, plus 10, 20 and 30 mg vialsNot stocked
Status in AustraliaRegistered as Mounjaro (prescription)Investigational, not on the ARTGRegistered as Ozempic and Wegovy (prescription)

Treat the weight numbers with care. Each comes from a separate trial with its own population and its own length, so lining them up is not a true comparison. Tirzepatide and retatrutide do share a 39-residue backbone and a common Lilly design approach, with a C20 fatty diacid attached so the peptide binds albumin.

Retatrutide vs Tirzepatide at the Receptor Level

Start with semaglutide, a pure GLP-1 drug. That one receptor accounts for its insulin-releasing effect, its slowing of gastric emptying and its appetite suppression. Tirzepatide brings in GIP as well, and it actually binds GIP more strongly than it binds GLP-1. Retatrutide keeps that GIP-leaning profile, which a 2024 structural study in Cell Discovery put at roughly 8.9 times the potency of native GIP, then layers on partial glucagon receptor activity at around 0.3 times native glucagon.

Glucagon signalling burns more energy and steers the liver toward fat breakdown. Researchers point to this when explaining the dramatic hepatic fat result from the 2024 Nature Medicine substudy, where 12 mg cut liver fat by 86.0% in relative terms over 48 weeks. It is also the reason retatrutide gets treated as a distinct line of inquiry, never as tirzepatide turned up louder. See what retatrutide is for a closer look at the molecule.

Weight Loss Outcomes, Trial by Trial

The list below runs in date order and covers the main obesity trial behind each drug. Every one enrolled adults without diabetes.

  • Semaglutide at 2.4 mg in STEP 1, reported by Wilding's group in NEJM in 2021. Over 68 weeks participants lost 14.9%, compared with 2.4% for placebo.
  • SURMOUNT-1, tirzepatide (NEJM, 2022, Jastreboff and colleagues). Across 72 weeks the 15 mg group lost 20.9%, the 10 mg group 19.5% and the 5 mg group 15.0%, while placebo lost 3.1%.
  • Phase 2, retatrutide (NEJM, 2023, Jastreboff and colleagues). After 48 weeks the 12 mg group had lost 24.2%, the 8 mg group 22.8% and the 4 mg group 17.1%, with placebo at 2.1%.
  • TRIUMPH-1, retatrutide (topline from Lilly, May 2026). At 80 weeks, average losses reached 19.0% on 4 mg, 25.9% on 9 mg and 28.3% on 12 mg.

One direct contest already exists between tirzepatide and semaglutide. SURMOUNT-5 (NEJM, 2025) found 20.2% weight loss with tirzepatide versus 13.7% with semaglutide over 72 weeks. For retatrutide the equivalent is TRIUMPH-5. About 800 adults are assigned at random to either drug, with body weight as the 80-week endpoint. Its estimated completion on ClinicalTrials.gov is December 2026. Until those results arrive, any verdict on which is better, tirzepatide or retatrutide, rests on comparisons between separate trials. Full timepoint figures are collected in our retatrutide results guide.

How the Side Effect Profiles Differ

Each of the three carries the familiar incretin pattern of nausea, vomiting, diarrhoea and constipation, which rises with dose and clusters during escalation. At the highest doses the figures look like this.

Tirzepatide 15 mg (SURMOUNT-1)Retatrutide 12 mg (TRIUMPH-1)Semaglutide 2.4 mg (STEP 1)
Vomiting12.2%25.3%about 25%
Nausea31.0%42.4%about 44%
Discontinuation on placebo2.6%4.9%3.1%
Discontinued for adverse events6.2%11.3%7.0%

Retatrutide shows one signal the other two lack. Dysesthesia, a change in how the skin perceives touch, turned up in TRIUMPH-4 in 20.9% of those on 12 mg, versus 0.7% of the placebo group. The older two drugs have another edge, namely several years of real-world safety monitoring since launch, which an unapproved compound simply cannot have. Our retatrutide side effects guide covers the detail.

Where Mounjaro, Ozempic and Wegovy Fit In

Mounjaro is simply the brand for tirzepatide, which the TGA first approved to treat type 2 diabetes and then, in September 2024, extended to chronic weight management in adults. Australian doctors prescribe Ozempic, a semaglutide brand, for type 2 diabetes, while Wegovy is the semaglutide brand approved for weight management. Each needs a prescription. Comparing retatrutide vs Mounjaro therefore means comparing it with tirzepatide, and retatrutide vs Ozempic is a matchup with diabetes-strength semaglutide, although the STEP 1 numbers come from Wegovy's higher 2.4 mg level.

For Australians the real divide is legal. Mounjaro and Ozempic went through TGA evaluation of quality, safety and efficacy, and retatrutide never has. The regulator has even warned people not to use it outside clinical trials. Note too that tirzepatide from a research peptide shop is a different thing from Mounjaro. No registration, no TGA review, and a sale restricted to laboratory use. Read is retatrutide available in Australia for the local position in full.

Picking Retatrutide vs Tirzepatide for Lab Work

In our experience labs seldom need to know which compound is better. What they need is to isolate one receptor's contribution. Tirzepatide has the bigger published literature and is better characterised, so it serves as the default dual-agonist control. Retatrutide is the one you vary when the question is what glucagon receptor activity adds, say in energy expenditure or hepatic lipid experiments. Plenty of designs include both, and a few add a third arm with cagrilintide, the long-acting amylin analogue, to cover satiety signalling through another route.

Format is another deciding factor. Research tirzepatide ships as the Tirzepatide Pen, built around a 3 mL cartridge. For retatrutide you can pick the 10 mg Retatrutide Pen or a vial of 10, 20 or 30 mg. Every lot of each passes the same independent tests, with identity confirmed by mass spectrometry and purity measured by HPLC, and the code on the vial label opens its certificate through the COA lookup. Reconstitution volumes can be worked out with the retatrutide calculator, and you will find both compounds in our metabolic research peptides collection.

Buy Retatrutide and Tirzepatide Together for Comparator Work

Running a head-to-head design? Sourcing both compounds from the same shop means the two certificates report identity and purity in the same format. Most comparator projects start with the 10 mg retatrutide vial plus the 2 mg tirzepatide vial, while labs preferring a comparator already in solution can choose the Tirzepatide Pen. For an amylin arm, add the 5 mg cagrilintide vial. Order the set online from AminoLab's Australian stock and include enough bacteriostatic water for every vial you intend to reconstitute.

AminoLab supplies these compounds to adults 18 and over for laboratory research use only, never for people or animals. Nothing written here is medical advice or an endorsement of personal use.

Frequently Asked Questions

Which gives more weight loss in trials, retatrutide or tirzepatide?

Looking across separate studies, its mean weight reductions were larger. TRIUMPH-1 recorded 28.3% at 80 weeks for retatrutide and its phase 2 study 24.2% at 48 weeks, while tirzepatide recorded 20.9% after 72 weeks in SURMOUNT-1. The trial designs differ, so this is not a like-for-like result. A true head-to-head, TRIUMPH-5, should wrap up toward the end of 2026.

How is retatrutide different from Mounjaro?

Mounjaro is the trade name for tirzepatide, which the TGA has registered on prescription for weight management and type 2 diabetes, and it acts on GIP and GLP-1. Retatrutide adds a third target, the glucagon receptor, and no regulator in Australia or overseas has approved it yet. Eli Lilly makes both.

How does retatrutide compare with Ozempic?

On cross-trial numbers retatrutide looks stronger for weight. Semaglutide 2.4 mg managed 14.9% across 68 weeks in STEP 1, where retatrutide's phase 2 study showed 24.2% across 48. Still, Ozempic carries TGA registration for diabetes and a long safety record, and retatrutide has no approval and nobody yet knows how safe it is over the long run. A fair verdict needs evidence nobody has yet.

Is research-grade tirzepatide equivalent to Mounjaro?

No. Mounjaro is a registered, prescription-only medicine produced under manufacturing the TGA has assessed. Tirzepatide from a research supplier matches the molecule on identity testing, yet it is unregistered, unreviewed by the TGA and sold for laboratory research only, never for human use.

Does AminoLab stock both compounds for Australian labs?

Yes, for laboratory research. AminoLab keeps both in Australian stock. Retatrutide is offered in three vial sizes plus a pen, and tirzepatide comes either as a 3 mL pen or a 2 mg vial. Using one source means every arm of the study is backed by certificates in the same layout. Neither is intended for human or veterinary use.

Popular Research Peptides

BPC-157

10 mg vial, 60 capsules

From $69

GHK-Cu

50 mg vial, 100 mg vial

From $49

Bacteriostatic Water

3 mL, 3 mL + 1 syringe, 10 mL, 10 mL + 1 syringe, 30 mL, 30 mL + 1 syringe

From $9
Certificate of analysisEvery research peptide comes with the certificate for its lot, listed in the COA library.
Tested identity and purityIdentity confirmed by mass spectrometry and purity measured by HPLC on every batch.
Australian stockOrders pack and ship from Australia with tracked Australia Post delivery. See delivery information.
Adults 18+ onlySold for laboratory research use only, under our research use policy.

Research use onlyAminoLab supplies research compounds for laboratory and in-vitro use, not for human or animal consumption. By continuing you confirm you are 18 or older and buying for research.

Leave